Evaxion Biotech Adopts Personalis Immune Profiling Platform for Melanoma Immunotherapy Trial

Source: Precision Oncology News, April 2022

NEW YORK – Personalized cancer therapy firm Evaxion Biotech and cancer genomics firm Personalis said on Tuesday that they will use Personalis’ immune profiling platform in a Phase IIb trial evaluating the efficacy and safety of Evaxion’s neoepitope-targeting therapy EVX-01, in combination with Merck’s Keytruda (pembrolizumab), for advanced melanoma patients.

Developed using Evaxion’s proprietary Pioneer Al technoligy, EVX-01 is one od the three patient-specific cancer treatments being advanced by the firm.

“With… Pioneer, we accurately predict the patient’s most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those exact mutations, not everything e;lse. That means a higher precision in the therapy than the standard-of-care teatments out there. “Evaxion CEO Lars Wegner said in a statement.

READ THE ORIGINAL FULL ARTICLE